潜江永安药业股份有限公司2026年第一次临时股东会决议公告

Group 1 - The company held its first extraordinary general meeting of shareholders on January 22, 2026, with no proposals being rejected [2] - A total of 472 shareholders attended the meeting, representing 77,785,386 shares, which is 26.9018% of the total voting shares [3][6] - The meeting was conducted in compliance with relevant laws and regulations, ensuring the legitimacy of the proceedings [13] Group 2 - The proposal to absorb the wholly-owned subsidiary Hubei Ling'an Technology Co., Ltd. was approved, with 77,522,786 shares in favor, accounting for 99.6624% of the valid votes [8][10] - The proposal to amend the "Compensation Management System for Directors and Senior Management" was also approved, with 77,422,086 shares in favor, representing 99.5329% of the valid votes [11][12] Group 3 - The meeting included participation from the company's directors, senior management, and witnessing lawyers, ensuring a comprehensive representation [7] - The legal opinion provided by Shanghai Jintiancheng (Wuhan) Law Firm confirmed that the meeting's procedures and voting results were valid and in accordance with the law [13][14]